Table 4.

The impact of enzyme-inducing antiseizure medications on apixaban levels (n = 152)

Model	ADS	EI-ASMs	Moderate inhibitor
A	0.28 (0.17–0.37)**	–	–
B	0.29 (0.19–0.38)**	– 0.41 (– 0.63 to – 0.18)**	–
C	0.28 (0.18–0.37)**	– 0.42 (– 0.64 to – 0.21)**	0.26 (0.06–0.45)*

Data are presented as coefficient (95% confidence interval). Model A evaluated the relation between log apixaban levels and apixaban dose score using a mixed-effects linear regression model. Model B included terms for ADS and EI-ASM. Model C included terms for ADS, EI-ASM, and moderate CYP3A4 inhibitors

ADS apixaban dose score, CYP cytochrome P450, EI-ASM enzyme-inducing antiseizure medications

*p < 0.05, **p < 0.001